NeuroMetrix, Inc., a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes. Its marketed products include Quell, a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems; DPNCheck, a test used to evaluate systemic neuropathies, such as diabetic peripheral neuropathy; ADVANCE system, a platform for the performance of traditional nerve conduction studies; and SENSUS, a pain therapy device based on transcutaneous electrical nerve stimulation for relief of chronic intractable pain. The company offers its products to consumers, retail merchandisers, direct response TV promoters, health care professionals, managed care organizations, endocrinologists, podiatrists, physicians, neurologists, and physical medicine and rehabilitation centers, as well as primary care, internal medicine, orthopedic, hand, and neurosurgeons. It operates in the United States, Europe, Japan, China, the Middle East, and Mexico. The company has a strategic collaboration with GlaxoSmithKline. NeuroMetrix, Inc. was founded in 1996 and is based in Woburn, Massachusetts.
IPO Year: 2004
Exchange: NASDAQ
Website: neurometrix.com
4 - NeuroMetrix, Inc. (0001289850) (Issuer)
4 - NeuroMetrix, Inc. (0001289850) (Issuer)
4 - NeuroMetrix, Inc. (0001289850) (Issuer)
4 - NeuroMetrix, Inc. (0001289850) (Issuer)
4 - NeuroMetrix, Inc. (0001289850) (Issuer)
4 - NeuroMetrix, Inc. (0001289850) (Issuer)
4 - NeuroMetrix, Inc. (0001289850) (Issuer)
4 - NeuroMetrix, Inc. (0001289850) (Issuer)
4 - NeuroMetrix, Inc. (0001289850) (Issuer)
4 - NeuroMetrix, Inc. (0001289850) (Issuer)
WOBURN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today reported financial and business highlights for the quarter and nine months ended September 30, 2024. The Company develops proprietary non-invasive medical devices for the diagnosis and treatment of pain and neurological disorders. NeuroMetrix, Inc. is actively pursuing its previously announced review of strategic options to enhance shareholder value. Over the past several quarters, the Company has strengthened its Board of Directors, terminated common stock sales under its ATM program, implemented a reduction-in-force, and phased-out its legacy ADVANCE® business. As a result, operating expenses and cash
WOBURN, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today for the purpose of clarity, reiterated that the Company is engaged in a review of strategic alternatives. In February of this year, the Company announced that it had initiated a review of strategic options with an objective of enhancing shareholder value. Over the past 6 months, the Company has invested considerable effort in evaluating a number of specific strategic directions and also making financial, operational and commercial optimizations. In collaboration with a financial advisor, the Company conducted an extensive survey of potential transactions. Detailed diligence was performed on multiple op
WOBURN, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today reported financial and business highlights for the quarter and six months ended June 30, 2024. The Company's mission is to reduce the impact of neurological disorders and pain syndromes through innovative non-invasive medical devices. In February of this year, the Company announced that it had initiated a review of strategic options with an objective of enhancing shareholder value. Over the past six months, the Company has invested considerable effort in evaluating a number of specific strategic directions and also making financial, operational and commercial optimizations. In collaboration with a fina
WOBURN, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) announced today that it plans to issue its 2024 second quarter business and financial highlights before the opening of the market on August 6, 2024. The Company will host a conference call at 8:00 a.m., Eastern Time on August 6, 2024. For participants who wish to access the Q2 2024 Conference Call live via telephone and be able to ask questions, please register in advance here. Upon registering, a dial-in and unique PIN will be provided on screen and via email to join the call. An audio-only webcast of the call, along with the earnings press release and accompanying condensed financial statements, may be acce
WOBURN, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today reported financial and business highlights for the quarter ended March 31, 2024. The Company's mission is to reduce the impact of neurological disorders and pain syndromes through innovative non-invasive medical devices. "We are focused on maximizing shareholder value," said Shai N. Gozani, M.D., Ph.D., Chief Executive Officer of NeuroMetrix. "Shareholders have recently provided valuable insights in addition to those of our financial advisor, Lucid Capital Markets (formerly Ladenburg Thalmann & Co.). Our process to evaluate strategic options has led to the expansion of our Board of Directors, and a decis
Joshua S. Horowitz joins Board of DirectorsAt-the-market equity facility terminated WOBURN, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today announced two steps to enhance shareholder value following feedback and recommendations from one of its largest shareholders, Ephraim Fields of Echo Lake Capital. The Board has approved the appointment of Joshua S. Horowitz as a new independent director with a 1-year term. Mr. Horowitz is a professional investor with over 22 years of investing experience. Since January 2012, he has served as a portfolio manager with Palm Management (US) LLC. Mr. Horowitz also brings extensive public company board experience. Earlie
WOBURN, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) noted the recent publication of a large study demonstrating that DPNCheck® combined with standard EKG or DPNCheck alone accurately detects diabetic peripheral neuropathy (DPN). Hayashi and colleagues evaluated 167 patients with Type 1 or Type 2 diabetes. The reference standard for DPN was a gold standard nerve conduction study. The authors developed a predictive formula based on DPNCheck measurements, patient age and the coefficient of variation of R-R intervals (CVR-R), which quantifies autonomic function and is a standard output of EKG machines. DPNCheck combined with CVR-R had high diagnostic performance
WOBURN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that over 2000 fibromyalgia patients have been prescribed Quell Fibromyalgia since its strategic commercial launch in December 2022. "We have been pleased by the positive response to Quell Fibromyalgia from providers taking care of patients with fibromyalgia during our strategic launch phase," said Shai N. Gozani, M.D., Ph.D., Chief Executive Officer of NeuroMetrix. "This early adoption affirms the need for novel clinical options to support fibromyalgia patients." Dr. Anjuli Desai, dual board certified in Pain Medicine and Physical Medicine and Rehabilitation, commented, "Quell Fibromyalgia
NURO stock price has declined 99% since its IPOGozani has received compensation of over $10 million since the IPOGozani was charged by the FTC for various wrongdoings at NUROGozani apparently personally paid the FTC $4 million as part of a settlementGozani barely owns any NURO sharesNURO continues to sell stock significantly below its net cash valueNEW YORK, NY / ACCESSWIRE / March 12, 2024 / Earlier today Echo Lake Capital sent a letter to the Board of Directors of Neurometrix, Inc. (NASDAQ:NURO). The letter listed the top ten reasons why the Board should immediately fire Shai Gozani, the company's longstanding Chairman and CEO. The reasons include (i) NURO's stock price has declined 99% si
- Stock trades significantly below its net cash per share- Questions the Board's ability and/or desire to create shareholder value- Notes tremendous destruction of shareholder value under company's leadership- Sees no reason for company to remain publicNEW YORK, NY / ACCESSWIRE / March 4, 2024 / On February 27, 2024, Ephraim Fields of Echo Lake Capital filed a Schedule 13D which included a letter to the Board of Directors of Neurometrix, Inc. (NASDAQ:NURO). The letter described his belief that the company should immediately liquidate because its stock price is trading significantly below net cash and because Mr. Fields sees no reason why the company should remain public. Among other things,
Joshua S. Horowitz joins Board of DirectorsAt-the-market equity facility terminated WOBURN, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today announced two steps to enhance shareholder value following feedback and recommendations from one of its largest shareholders, Ephraim Fields of Echo Lake Capital. The Board has approved the appointment of Joshua S. Horowitz as a new independent director with a 1-year term. Mr. Horowitz is a professional investor with over 22 years of investing experience. Since January 2012, he has served as a portfolio manager with Palm Management (US) LLC. Mr. Horowitz also brings extensive public company board experience. Earlie
WOBURN, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that it has appointed Jonathan "Breck" Harmel as National Director of Sales, Neuromodulation. Mr. Harmel will be responsible for leading the sales organization for the Company's prescription wearable neurotherapeutics business in the U.S. market. The Company recently received FDA De Novo authorization to market its Quell® device as an aid for reducing the symptoms of fibromyalgia in adults with high pain sensitivity. The Company received FDA Breakthrough Designation for the use of Quell to treat fibromyalgia in July 2021. Mr. Harmel brings 15 years of experience in high growth medical technol
WOBURN, Mass., June 28, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today announced the appointment of Bradley M. Fluegel to its Board of Directors, effective as of July 1, 2022. Mr. Fluegel has a broad commercial and advisory background with concentrated industry experience in healthcare and medical technology. He has held numerous leadership roles over the past 25+ years, primarily in healthcare strategy and business development. Most recently, Mr. Fluegel was Senior Vice President, Chief Healthcare Commercial Market Development Officer for Walgreens Co. In this role he was responsible for leading all commercial healthcare activities, including sales and contracting, biopha
WOBURN, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that it has appointed Brandi Damkier as Vice President, Clinical Partnerships. Ms. Damkier will be responsible for expanding the Company's DPNCheck® clinical partnerships and advancing the Company's footprint in the value-based healthcare market. DPNCheck is a widely used point-of-care test that provides physicians with fast, accurate and cost-effective screening, diagnosis and monitoring of peripheral neuropathies. It is often used to stage the severity of Diabetic Peripheral Neuropathy (DPN), which is the most common specific cause of peripheral nerve disease and a ubiquitous long-term compli
WOBURN, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that it has appointed Susan M. Bell as Senior Vice President, Population Health & Value Based Care. Ms. Bell will be responsible for growing the Company's DPNCheck® business with a primary focus on the Medicare Advantage population, and more broadly, expanding the Company's footprint in the value-based healthcare market. DPNCheck is a widely used point-of-care test that provides physicians with fast, accurate and cost-effective screening, diagnosis and monitoring of peripheral neuropathies. It is often used to stage the severity of Diabetic Peripheral Neuropathy (DPN), which is the most common
10-Q - NeuroMetrix, Inc. (0001289850) (Filer)
8-K - NeuroMetrix, Inc. (0001289850) (Filer)
10-Q - NeuroMetrix, Inc. (0001289850) (Filer)
8-K - NeuroMetrix, Inc. (0001289850) (Filer)
SD - NeuroMetrix, Inc. (0001289850) (Filer)
S-8 - NeuroMetrix, Inc. (0001289850) (Filer)
10-Q - NeuroMetrix, Inc. (0001289850) (Filer)
8-K - NeuroMetrix, Inc. (0001289850) (Filer)
8-K - NeuroMetrix, Inc. (0001289850) (Filer)
DEFA14A - NeuroMetrix, Inc. (0001289850) (Filer)
SC 13G - NeuroMetrix, Inc. (0001289850) (Subject)
SC 13D/A - NeuroMetrix, Inc. (0001289850) (Subject)
SC 13D - NeuroMetrix, Inc. (0001289850) (Subject)
SC 13D - NeuroMetrix, Inc. (0001289850) (Subject)
SC 13G/A - NeuroMetrix, Inc. (0001289850) (Subject)
SC 13G/A - NeuroMetrix, Inc. (0001289850) (Subject)
SC 13G/A - NeuroMetrix, Inc. (0001289850) (Subject)
SC 13G - NeuroMetrix, Inc. (0001289850) (Subject)
WOBURN, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today reported financial and business highlights for the quarter and six months ended June 30, 2024. The Company's mission is to reduce the impact of neurological disorders and pain syndromes through innovative non-invasive medical devices. In February of this year, the Company announced that it had initiated a review of strategic options with an objective of enhancing shareholder value. Over the past six months, the Company has invested considerable effort in evaluating a number of specific strategic directions and also making financial, operational and commercial optimizations. In collaboration with a fina
WOBURN, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) announced today that it plans to issue its 2024 second quarter business and financial highlights before the opening of the market on August 6, 2024. The Company will host a conference call at 8:00 a.m., Eastern Time on August 6, 2024. For participants who wish to access the Q2 2024 Conference Call live via telephone and be able to ask questions, please register in advance here. Upon registering, a dial-in and unique PIN will be provided on screen and via email to join the call. An audio-only webcast of the call, along with the earnings press release and accompanying condensed financial statements, may be acce
WOBURN, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) announced today that it plans to issue its 2023 fourth quarter and year end business and financial highlights before the opening of the market on February 22, 2024. The Company will host a conference call at 8:00 a.m., Eastern Time on February 22, 2024. For participants who wish to access the Q4 and year end 2023 Conference Call live via telephone and be able to ask questions, please register in advance here. Upon registering, a dial-in and unique PIN will be provided on screen and via email to join the call. An audio-only webcast of the call, along with the earnings press release and accompanying condensed f
WOBURN, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today reported business and financial highlights for the quarter and nine month period ended September 30, 2023. The Company's mission is to reduce the impact of neurological disorders and pain syndromes through innovative non-invasive medical devices. "We continue to be encouraged by the market response to Quell® Fibromyalgia during its strategic launch. We now have field sales capabilities in the key markets of Texas, Florida and California," said Shai N. Gozani, M.D., Ph.D., Chief Executive Officer of NeuroMetrix. "We intend to further expand our physician sales capabilities to support Quell Fibromyalg
WOBURN, Mass., Oct. 23, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) announced today that it plans to issue its Q3 2023 business and financial highlights before the opening of the market on October 26, 2023. The Company will host a conference call at 8:00 a.m., Eastern Time on October 26, 2023. For participants who wish to access the Q3 2023 Conference Call live via telephone and be able to ask questions, please register in advance here. Upon registering, a dial-in and unique PIN will be provided on screen and via email to join the call. An audio-only webcast of the call, along with the earnings press release and accompanying condensed financial statements, may be accessed in
WOBURN, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today reported business and financial highlights for the quarter and six months period ended June 30, 2023. The Company's mission is to reduce the impact of neurological disorders and pain syndromes through innovative non-invasive medical devices. "We have taken an important step to expand the availability of Quell® Fibromyalgia in key U.S. markets," said Shai N. Gozani, M.D., Ph.D., Chief Executive Officer of NeuroMetrix. "This follows positive evidence of physician and patient traction from our strategic launch this year. Also, we were encouraged by recently reported results from a phase 2 randomized contro
WOBURN, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) announced today that it plans to issue its Q2 2023 business and financial highlights before the opening of the market on July 27, 2023. The Company will host a conference call at 8:00 a.m., Eastern Time on July 27, 2023. For participants who wish to access the Q2 2023 Conference Call live via telephone and be able to ask questions, please register in advance here. Upon registering, a dial-in and unique PIN will be provided on screen and via email to join the call. An audio-only webcast of the call, along with the earnings press release and accompanying condensed financial statements, may be accessed in the In
WOBURN, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today reported financial and business highlights for the quarter ended March 31, 2023. The Company's mission is to reduce the impact of neurological disorders and pain syndromes on individuals and on population health through innovative non-invasive medical devices. Q1 Highlights: Q1 2023 revenue was $1.7 million, a decrease of 25.1% from $2.3M in the first quarter of 2022. The primary reason was that DPNCheck® sales declined due to a suspension of screening programs, including DPNCheck, by the Company's largest Medicare Advantage customer. This drop was partially offset by increased sales to other Medicare A
WOBURN, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) announced today that it plans to issue its 2023 first quarter financial results before the opening of the market on May 3, 2023. The Company will host a conference call at 8:00 a.m., Eastern Time on May 3, 2023 to discuss its financial results as well as business developments affecting the Company. For participants who wish to access the Earnings Call live via telephone and be able to ask questions, please register in advance here. Upon registering, a dial-in and unique PIN will be provided on screen and via email to join the call. An audio-only webcast of the call, along with the earnings press release and
WOBURN, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2022. The Company's mission is to reduce the impact of neurological disorders and pain syndromes on individuals and on population health through innovative non-invasive medical devices. Q4 Highlights: Q4 2022 revenue was $1.8 million, an increase of 1.5% from the fourth quarter of 2021. DPNCheck® sales, the Company's largest revenue contributor, increased by 18.1%. This included growth of 20.6% in the domestic Medicare Advantage market and 8.6% in international sales. Medicare Advantage growth was primarily orga
NeuroMetrix (NASDAQ:NURO) reported quarterly losses of $(1.67) per share. This is a 1.83 percent decrease over losses of $(1.64) per share from the same period last year. The company reported $1.09 million in sales this quarter. This is a 36.64 percent decrease over sales of $1.73 million the same period last year.
Gainers Mobile-health Network (NASDAQ:MNDR) shares increased by 34.7% to $27.44 during Friday's regular session. The market value of their outstanding shares is at $932.9 million. NKGen Biotech (NASDAQ:NKGN) stock increased by 19.76% to $1.03. The company's market cap stands at $23.4 million. The company's, Q4 earnings came out 3 days ago. Kintara Therapeutics (NASDAQ:KTRA) stock increased by 18.57% to $0.13. The market value of their outstanding shares is at $4.9 million. NeuroMetrix (NASDAQ:NURO) stock moved upwards by 17.26% to $4.28. The company's market cap stands at $8.5 million. Inspire Veterinary (NASDAQ:IVP) shares moved upwards by 17.24% to $0.05. The company's market cap stan
NeuroMetrix, Inc. (NASDAQ:NURO) today announced that over 2000 fibromyalgia patients have been prescribed Quell Fibromyalgia since its strategic commercial launch in December 2022."We have been pleased by the positive response to Quell Fibromyalgia from providers taking care of patients with fibromyalgia during our strategic launch phase," said Shai N. Gozani, M.D., Ph.D., Chief Executive Officer of NeuroMetrix. "This early adoption affirms the need for novel clinical options to support fibromyalgia patients."Dr. Anjuli Desai, dual board certified in Pain Medicine and Physical Medicine and Rehabilitation, commented, "Quell Fibromyalgia has been the treatment option that I have been awaiting
- Stock trades significantly below its net cash per share- Questions the Board's ability and/or desire to create shareholder value- Notes tremendous destruction of shareholder value under company's leadership- Sees no reason for company to remain publicNEW YORK, NY / ACCESSWIRE / March 4, 2024 / On February 27, 2024, Ephraim Fields of Echo Lake Capital filed a Schedule 13D which included a letter to the Board of Directors of Neurometrix, Inc. (NASDAQ:NURO). The letter described his belief that the company should immediately liquidate because its stock price is trading significantly below net cash and because Mr. Fields sees no reason why the company should remain public. Among other things,
NeuroMetrix (NASDAQ:NURO) reported quarterly losses of $(1.43) per share. This is a decrease over losses of $(0.73) per share from the same period last year. The company reported $1.32 million in sales this quarter. This is a 28.70 percent decrease over sales of $1.85 million the same period last year.
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on revenue of $260.00 million. • Bausch Health Companies (NYSE:BHC) is expected to report quarterly earnings at $1.02 per share on revenue of $2.30 billion. • H&E Equipment Servs (NASDAQ:HEES) is estimated to report quarterly earnings at $1.22 per share on revenue of $382.59 million. • Installed Building Prods (NYSE:IBP) is expected to report quarterly earnings at $2.45 per share on revenue of $682.48 million. • Keurig Dr Pepper (NASDAQ:KDP) is likely to report quarterly earnings at $0.54 per share on revenue of $3.91 billion. • MGP Ingredients (NASDAQ:MGPI) is expecte
- SEC Filing